Table 2 Table of events
| Event | Presentation until start of iloprost or NaCl 0.9% | d1 | d2 | d3 | d4 | d5 | d6–d27 | Hospital discharge or d28 | Hospital discharge or d90 | d180 ± 14d |
|---|---|---|---|---|---|---|---|---|---|---|
| Informed consent | X | |||||||||
| Inclusion/exclusion criteria | X | |||||||||
| Pregnancy test in women of childbearing age | X | |||||||||
| Demographics | X | |||||||||
| Medical history | X | |||||||||
| Randomization | X | |||||||||
| Iloprost or NaCl 0.9% (control) | X | X | X | X | X | |||||
| Clinical assessment including outcome | X | X | X | X | X | X | X | X | X | |
| Laboratory testing | X | X | X | X | X | X | X | X | ||
| Adverse/serious adverse event monitoring | X | X | X | X | X | X | X | |||
| Plasma biomarkers | X | X | X | X | X | X | ||||
| Barthel Index | X | X | X | X | ||||||
| SOFA score | X | X | X | X | X | X | X | X | ||
| Health-related questionnaire | X | |||||||||
| VES | X |